Emtricitabine vs Emtricitabine and Tenofovir Disoproxil — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Emtricitabine

Brand: Emtriva

First FDA approval: 2003-07-02

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Emtricitabine and Tenofovir Disoproxil

Brand: Truvada

First FDA approval: 2004-08-02

Lowest NADACAcquisition cost floor across all NDCs

$14.51Per unit

$0.457Per unit

Average NADACAcross all dosage forms and strengths

$15.49Up to $17.44

$5.37Up to $59.79

Generic manufacturersActive ANDA holders — FDA Orange Book

22 total ANDAs filed

1022 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$3.0MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

8K2K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$386Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes2 manufacturers

Yes10 manufacturers